previous or ongoing coronavirus disease-19 (covid-19). coagulation disorders, other conditions associated with prolonged bleeding time or anticoagulant treatments, which according to the investigator contraindicate intramuscular injection. conditions which can be corrected with measures such as platelet concentrate treatments, coagulation factors or other measures for people responsible for anticoagulants are not exclusion criteria. planned to receive another vaccine within 14 days before the first dose of the study vaccine, or during the period from the first dose of the study vaccine up to 14 days after the second dose of the study vaccine, and vaccination with another vaccine which in the investigator's opinion cannot be planned outside these time periods pregnancy or breast feeding. hypersensitivity to the active substance or to any of the excipients contained in the vaccine individuals who cannot understand the informed consent. individuals who for other reasons are considered by investigators as not suitable for inclusion

previous or ongoing coronavirus disease-19 (covid-19). coagulation disorders, other conditions associated with prolonged bleeding time or anticoagulant treatments, which according to the investigator contraindicate intramuscular injection. conditions which can be corrected with measures such as platelet concentrate treatments, coagulation factors or other measures for people responsible for anticoagulants are not exclusion criteria. planned to receive another vaccine within 14 days before the first dose of the study vaccine, or during the period from the first dose of the study vaccine up to 14 days after the second dose of the study vaccine, and vaccination with another vaccine which in the investigator's opinion cannot be planned outside these time periods pregnancy or breast feeding. hypersensitivity to the active substance or to any of the excipients contained in the vaccine individuals who cannot understand the informed consent. individuals who for other reasons are considered by investigators as not suitable for inclusion

1. previous or ongoing coronavirus disease-19 (covid-19). 2. coagulation disorders, other conditions associated with prolonged bleeding time or anticoagulant treatments, which according to the investigator contraindicate intramuscular injection. conditions which can be corrected with measures such as platelet concentrate treatments, coagulation factors or other measures for people responsible for anticoagulants are not exclusion criteria. 3. planned to receive another vaccine within 14 days before the first dose of the study vaccine, or during the period from the first dose of the study vaccine up to 14 days after the second dose of the study vaccine, and vaccination with another vaccine which in the investigator's opinion cannot be planned outside these time periods 4. pregnancy or breast feeding. 5. hypersensitivity to the active substance or to any of the excipients contained in the vaccine 6. individuals who cannot understand the informed consent. 7. individuals who for other reasons are considered by investigators as not suitable for inclusion

1. previous or ongoing coronavirus disease-19 (covid-19). 2. coagulation disorders, other conditions associated with prolonged bleeding time or anticoagulant treatments, which according to the investigator contraindicate intramuscular injection. conditions which can be corrected with measures such as platelet concentrate treatments, coagulation factors or other measures for people responsible for anticoagulants are not exclusion criteria. 3. planned to receive another vaccine within 14 days before the first dose of the study vaccine, or during the period from the first dose of the study vaccine up to 14 days after the second dose of the study vaccine, and vaccination with another vaccine which in the investigator's opinion cannot be planned outside these time periods 4. pregnancy or breast feeding. 5. hypersensitivity to the active substance or to any of the excipients contained in the vaccine 6. individuals who cannot understand the informed consent. 7. individuals who for other reasons are considered by investigators as not suitable for inclusion